Abstract
Purpose
The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS).
Methods
The related literatures published until April 2021 were searched in PubMed, Cochrane Library, MEDLINE and EmBase.
Results
Six randomized controlled trials of 127 related articles were obtained through searching. Three articles compared liraglutide with metformin, and four articles compared liraglutide combined with metformin with metformin. Our meta-analysis suggests that liraglutide was superior to metformin only in weight loss [MD = − 2.74, 95% CI (− 4.29, − 1.18), P = 0.0006]. Compared with metformin group, the combination group had significant advantages in weight loss [MD = − 3.81, 95% CI (− 5.16, − 2.46), P < 0.001], BMI [MD = − 2.59, 95% CI (− 3.12, − 2.07), P < 0.001], waist circumference [MD = − 6.26, 95% CI (− 7.79, − 4.72), P < 0.001], fasting blood glucose [MD = − 0.59, 95% CI (− 0.74, − 0.44), P < 0.001] and fasting insulin [MD = − 1.52, 95% CI (− 2.69, − 0.35), P = 0.01], while the incidence of adverse reactions was relatively high [RR = 2.91, 95% CI (1.55, 5.46), P = 0.00009].
Conclusion
The present results indicate that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients. Liraglutide combined with metformin is more effective than metformin in improving PCOS, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions.
Similar content being viewed by others
References
Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C et al (2020) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 67:1–8
Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised (2003) consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
Mahalingaiah S, Diamanti-Kandarakis E (2015) Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets 19:1561–1574
Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC (2020) Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta 502:214–221
Pepene CE, Ilie IR, Marian I, Duncea I (2011) Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur J Endocrinol 164:61–68
Krentowska A, Łebkowska A, Jacewicz-Święcka M, Hryniewicka J, Leśniewska M et al (2021) Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome. Endocrine 72(2):400–410
Ilie IR, Marian I, Mocan T, Ilie R, Mocan L et al (2012) Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? BMC Endocr Disord 12:9
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, International PCOS Network et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 33(9):1602–1618
Palomba S, Falbo A, Zullo F, Orio F Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30:1–50
Dunaif A (2008) Medicine insight: insulin-sensitizing medicines in the treatment of polycystic ovary syndrome-a reappraisal. Nat Clin Pract Endocrinol Metab 4:272–283
Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162:193–212
Lim SS, Davies MJ, Norman RJ, Moran LJ (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 18:618–637
Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P et al (2007) Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500–2515
Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 10:155
Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A et al (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18:1928–1932
Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Haseltine F, Merriam GR (eds) Polycystic ovary syndrome. Blackwell Scientific Publications, Boston, pp 377–384
Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Chichester, England
Wang FF, Wu Y, Zhu YH, Ding T, Batterham RL (2018) Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obes Rev 19:1424–1445
Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A (2015) Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 8:32
Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A (2014) Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 170:451–459
Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A (2015) A 12-week treatment with the long-acting GLP-1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens) 14:81–90
Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E (2018) Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol 179:1–11
Jensterle M, Kravos NA, Goricar K, Janez A (2017) Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 17:5
Huang ZS, Luan LL, Yang J, Huang ZX, Wang CY et al (2015) Efficacy of liraglutide on metabolic parameters and pregnancy in polycystic ovary syndrome patients combined with impaired glucose tolerance and obesity. Chin J Diabetes Mellitus 7:437–441 (in Chinese)
Chou KH, von Eye CH, Capp E, Spritzer PM (2003) Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 35:86–91
Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ et al (2015) Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 21:560–574
De Sloover KY, Ernst ME (2001) Use of metformin in polycystic ovary syndrome. Ann Pharmacother 35:1644–1647
Ladenheim EE (2015) Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther 9:1867–1875
Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742
Dailey MJ, Moran TH (2013) Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 24:85–91
Van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221:T1-16
Marathe CS, Rayner CK, Jones KL, Horowitz M (2011) Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011:279530
Rachoń D, Teede H (2010) Ovarian function and obesity–interrelationship, impact on women’s reproductive lifespan and treatment options. Mol Cell Endocrinol 316:172–179
Cena H, Chiovato L, Nappi RE (2020) Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab 105:e2695–e2709
Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S et al (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1–P29
Niafar M, Pourafkari L, Porhomayon J, Nader N (2016) A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet 293:509–515
Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ et al (2018) Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab 20:215–218
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R (2008) Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:2670–2678
Hoang V, Bi J, Mohankumar SM, Vyas AK (2015) Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS ONE 10:e0126119
Gadde KM, Martin CK, Berthoud HR, Heymsfield SB (2018) Obesity: pathophysiology and management. J Am Coll Cardiol 71(1):69–84
Jensterle M, Kravos NA, Goričar K, Janez A (2017) Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 17(1):5
Siamashvili M, Davis SN (2021) Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol 27:1–9
Papaetis GS, Filippou PK, Constantinidou KG, Stylianou CS (2020) Liraglutide: new perspectives for the treatment of polycystic ovary syndrome. Clin Drug Investig 40(8):695–713
Funding
This research did not receive any specific grant from funding agencies.
Author information
Authors and Affiliations
Contributions
J. J. Ge and D. J. Wang wrote the manuscript. J. J. Ge and W. Song analyzed data. S. M. Shen and W. H. Ge edited and approved this manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
This article does not include research on human participants and/or animals.
Informed consent
Informed consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ge, J., Wang, D., Song, W. et al. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest 45, 261–273 (2022). https://doi.org/10.1007/s40618-021-01666-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-021-01666-6